卫光生物(002880.SZ)：皮下注射人免疫球蛋白收到药品注册临床试验受理通知书

Core Viewpoint - Weigao Biologics (002880.SZ) has received a clinical trial application acceptance notice from the National Medical Products Administration for subcutaneous immunoglobulin production, indicating progress in its drug development pipeline [1] Group 1: Company Developments - Weigao Biologics has been granted the acceptance notice for the clinical trial application of subcutaneous immunoglobulin (SCIG) [1] - SCIG contains broad-spectrum antibodies, specifically immunoglobulin G (IgG), which can enhance the IgG levels in patients [1] - The product aims to neutralize toxins and assist in the elimination of bacteria, viruses, and other pathogens, thereby improving the immune response and infection resistance [1]